Skip to main content
SpringerLink
Log in

PSOLAR registry shows ustekinumab does not increase risk of MACE

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Bissonnette R, et al. Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. Drug Safety : 2 Jun 2021. Available from: URL: http://doi.org/10.1007/s40264-021-01065-z

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PSOLAR registry shows ustekinumab does not increase risk of MACE. Reactions Weekly 1860, 13 (2021). https://doi.org/10.1007/s40278-021-97468-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-97468-3

Search

Navigation